This website uses cookies primarily for visitor analytics. Certain pages will ask you to fill in contact details to receive additional information. On these pages you have the option of having the site log your details for future visits. Indicating you want the site to remember your details will place a cookie on your device. To view our full cookie policy, please click here. You can also view it at any time by going to our Contact Us page.

Magnetic helmet successfully shrinks deadliest brain cancer tumour

28 July 2021

Neurological researchers have managed to shrink a glioblastoma tumour, which is nearly always fatal, by more than a third in first-in-world human test.

Credit: Houston Methodist
Credit: Houston Methodist

Houston Methodist Neurological Institute researchers from the department of neurosurgery shrunk a deadly glioblastoma tumour by more than a third using a helmet generating a non-invasive oscillating magnetic field that the patient wore on his head while administering the therapy in his own home. 

The 53-year-old patient died from an unrelated injury about a month into the treatment, but during that short time, 31 percent of the tumour mass disappeared. The autopsy of his brain confirmed the rapid response to the treatment.

"Thanks to the courage of this patient and his family, we were able to test and verify the potential effectiveness of the first non-invasive therapy for glioblastoma in the world," said David S. Baskin, M.D., FACS, FAANS, corresponding author and Director of the Kenneth R. Peak Center for Brain and Pituitary Tumour Treatment in the Department of Neurosurgery at Houston Methodist. 

"The family's generous agreement to allow an autopsy after their loved ones' untimely death made an invaluable contribution to the further study and development of this potentially powerful therapy."

In a case study published in Frontiers in Oncology, Baskin and his colleagues detailed the journey of their pioneering patient who suffered from end-stage recurrent glioblastoma, despite a radical surgical excision, chemoradiotherapy and experimental gene therapy.

Glioblastoma is the deadliest of brain cancers in adults, nearly always fatal, with a life expectancy of a few months to two years. When the patient's glioblastoma recurred in August 2019, Baskin and his team, already working on the OMF treatment in mouse models, received FDA approval for compassionate-use treatment of the patient with their newly invented Oncomagnetic Device under an Expanded Access Program (EAP). The protocol also was approved by the Houston Methodist Research Institute Institutional Review Board.

The treatment consisted of intermittent application of an oscillating magnetic field generated by rotating permanent magnets in a specific frequency profile and timing pattern. First administered for two hours under supervision in the Peak Clinic, ensuing treatments were given at home with help from the patient's wife, with increasing treatment times up to a maximum of only six hours per day.

The Oncomagnetic Device looks deceptively simple: three oncoscillators securely attached to a helmet and connected to a microprocessor-based electronic controller operated by a rechargeable battery, an invention by case study co-author Dr. Santosh Helekar. During the patient's five weeks of treatment, the magnetic therapy was well tolerated and the tumour mass and volume shrunk by nearly a third, with shrinkage appearing to correlate with the treatment dose.

"Imagine treating brain cancer without radiation therapy or chemotherapy," said Baskin. "Our results in the laboratory and with this patient open a new world of non-invasive and nontoxic therapy for brain cancer, with many exciting possibilities for the future."

Co-authored by Associate Professor of neurosurgery Santosh Helekar, M.D., Ph.D., research professor Martyn A. Sharpe, Ph.D., and biomedical engineer Lisa Nguyen, the case study is entitled, "Case Report: End-Stage Recurrent Glioblastoma Treated with a New Noninvasive Non-Contact Oncomagnetic Device." The ongoing research is supported by the Translational Research Initiative of the Houston Methodist Research Institute, Donna and Kenneth Peak, the Kenneth R. Peak Foundation, the John S. Dunn Foundation, the Taub Foundation, the Blanche Green Fund of the Pauline Sterne Wolff Memorial Foundation, the Kelly Kicking Center Foundation, the Gary and Marlee Swarz Foundation, the Methodist Hospital Foundation and the Veralan Foundation.


Print this page | E-mail this page